Hirotaka Shinomiya1, Shingo Hasegawa1, Daisuke Yamashita1, Yasuo Ejima2, Yoshida Kenji2, Naoki Otsuki1, Naomi Kiyota3, Shunsuke Sakakibara4, Tadashi Nomura4, Kazunobu Hashikawa4, Eiji Kohmura5, Ryohei Sasaki2, Ken-Ichi Nibu1. 1. Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, Chuo-Ku, Kobe, Hyogo, Japan. 2. Department of Radiation Oncology, Kobe University Graduate School of Medicine, Chuo-Ku, Kobe, Hyogo, Japan. 3. Department of Medical Oncology/Hematology, Kobe University Graduate School of Medicine, Chuo-Ku, Kobe, Hyogo, Japan. 4. Department of Plastic Surgery, Kobe University Graduate School of Medicine, Chuo-Ku, Kobe, Hyogo, Japan. 5. Department of Neurosurgery, Kobe University Graduate School of Medicine, Chuo-Ku, Kobe, Hyogo, Japan.
Abstract
BACKGROUND: The purpose of this study was to analyze outcomes for the treatment of locally advanced temporal bone cancer by means of concomitant chemoradiotherapy (CCRT) with a combination of cisplatin (CDDP), 5-fluorouracil (5-FU), and docetaxel (TPF). METHODS: Between 2006 and 2011, 34 patients with squamous cell carcinoma of the temporal bone were treated at Kobe University Hospital. Medical records were retrospectively reviewed to obtain information concerning patient characteristics, extent of disease, treatment, adverse events, and oncologic results. RESULTS: Ten patients were treated with CCRT using TPF regimen. The 5-year overall survival rate and disease-free survival rate were both 60%. Of special interest is that even for patients with unresectable T4 disease, the 5-year overall survival rate was 56%. CONCLUSION: The results of our study indicate that CCRT with TPF for locally advanced temporal bone cancer is an effective and promising regimen.
BACKGROUND: The purpose of this study was to analyze outcomes for the treatment of locally advanced temporal bone cancer by means of concomitant chemoradiotherapy (CCRT) with a combination of cisplatin (CDDP), 5-fluorouracil (5-FU), and docetaxel (TPF). METHODS: Between 2006 and 2011, 34 patients with squamous cell carcinoma of the temporal bone were treated at Kobe University Hospital. Medical records were retrospectively reviewed to obtain information concerning patient characteristics, extent of disease, treatment, adverse events, and oncologic results. RESULTS: Ten patients were treated with CCRT using TPF regimen. The 5-year overall survival rate and disease-free survival rate were both 60%. Of special interest is that even for patients with unresectable T4 disease, the 5-year overall survival rate was 56%. CONCLUSION: The results of our study indicate that CCRT with TPF for locally advanced temporal bone cancer is an effective and promising regimen.
Authors: Kristen L Seligman; Daniel Q Sun; Patrick P Ten Eyck; Nathan M Schularick; Marlan R Hansen Journal: Laryngoscope Date: 2019-03-15 Impact factor: 3.325
Authors: Cindy H Nabuurs; Wietske Kievit; C René Leemans; Conrad F G M Smit; Michiel W M van den Brekel; Robert J Pauw; Bernard F A M van der Laan; Jeroen C Jansen; Martin Lacko; Weibel W Braunius; Chunfu Dai; Xunbei Shi; Giovanni Danesi; Jan Bouček; Robert P Takes; Henricus P M Kunst Journal: Head Neck Date: 2022-05-13 Impact factor: 3.821